Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patent exclusivity

- PMLiVE

NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales

In England, more than six million people live with cardiovascular disease, costing the NHS around £7.4bn per year

- PMLiVE

CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

The drug is recommended for use in adult patients who are already receiving statin treatment

- PMLiVE

Amarin shares tumble following Vascepa patent loss

Judgement invalidates six key patents on fish-oil derived med

- PMLiVE

Northsea Therapeutics raises $40m to develop fish oil NASH drug

Looking for mid-stage trial success in field littered with failures

- PMLiVE

FDA okays Amarin’s Vascepa for cardiovascular risk reduction

Drug is on course for blockbuster sales

- PMLiVE

Amarin files fish oil-based heart drug Vascepa in Europe

FDA verdict is also due for expanded use of the drug

- PMLiVE

Amarin wins FDA advisory nod for Vascepa cardiovascular expansion

Approval likely for fish-oil derived drug following speedy review

- PMLiVE

Amarin up as FDA speeds Vascepa’s cardiovascular claim review

Advance fuels takeover talk

- PMLiVE

Pfizer takeover rumour ignites Amarin shares

Fish oil product shows great promise

- PMLiVE

Amarin hits jackpot with astonishing heart benefits from fish oil product

Purified fish oil could be a game-changer

- PMLiVE

Amarin sues FDA over off-label policy

Claims block on discussing off-label uses conflicts freedom of speech

- PMLiVE

Amarin slides as FDA panel votes against fish oil therapy

Advisory committee wants more data on Vascepa

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links